Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $19.2857.

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Candel Therapeutics in a research report on Thursday. Stifel Nicolaus started coverage on Candel Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $22.00 price objective for the company. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Cantor Fitzgerald began coverage on Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Friday, July 17th.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the transaction, the chief technology officer directly owned 83,865 shares of the company’s stock, valued at approximately $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the transaction, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This trade represents a 23.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 14.30% of the company’s stock.

Hedge Funds Weigh In On Candel Therapeutics

Several large investors have recently added to or reduced their stakes in CADL. Moneta Group Investment Advisors LLC boosted its stake in Candel Therapeutics by 4.9% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock valued at $240,000 after purchasing an additional 2,000 shares during the last quarter. Invesco Ltd. raised its stake in shares of Candel Therapeutics by 29.0% in the fourth quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock worth $85,000 after purchasing an additional 3,380 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Candel Therapeutics by 12.6% in the first quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock valued at $149,000 after purchasing an additional 3,400 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Candel Therapeutics by 25.5% in the fourth quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock valued at $110,000 after purchasing an additional 3,955 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after buying an additional 4,439 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Down 0.7%

Candel Therapeutics stock opened at $11.72 on Friday. The company has a market capitalization of $858.72 million, a PE ratio of -8.31 and a beta of -0.51. Candel Therapeutics has a 12-month low of $4.35 and a 12-month high of $11.95. The firm’s fifty day moving average is $9.68 and its 200 day moving average is $7.40. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). As a group, sell-side analysts predict that Candel Therapeutics will post -0.91 EPS for the current fiscal year.

More Candel Therapeutics News

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $23 price target, implying substantial potential upside from recent trading levels. The firm’s outlook reflects expectations for future earnings growth and progress in Candel’s pipeline. HC Wainwright reaffirms Buy rating and price target
• Positive Sentiment: Management highlighted “meaningful execution” toward a biologics license application (BLA) submission in the fourth quarter. Candel is targeting its first commercial product in 2027, making regulatory progress a key catalyst for the stock. CADL rises as biotech targets 2027 commercial launch
• Neutral Sentiment: Bank of America raised its price target from $9 to $12 but maintained a Neutral rating. The revised target is close to the recent share price, suggesting the analyst sees limited near-term upside despite the higher valuation estimate. Bank of America raises CADL price target
• Negative Sentiment: Candel reported a second-quarter loss of $0.52 per share, substantially worse than the $0.27 consensus estimate. The earnings miss highlights continued cash-burn and execution risk for the clinical-stage biotechnology company. Candel second-quarter earnings release
• Negative Sentiment: HC Wainwright modestly reduced its FY2028 and FY2029 EPS estimates to $0.69 and $1.41, respectively. Although the firm retained its Buy rating and $23 target, the estimate cuts indicate slightly lower expectations for Candel’s long-term profitability.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.